KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.¹

All patient imagery on this webpage is fictional and used for illustrative purposes only.

Women of childbearing potential should use effective contraception (methods that result in less than 1% pregnancy rates) while receiving KESIMPTA and for 2 months after the last administration.

For full safety information, please refer to the KESIMPTA Summary of Product Characteristics (SmPC).¹

Watch this video to learn more about how to use KESIMPTA. This will help you teach your patients how to administer KESIMPTA with the Sensoready® pen after the initial dose.

If you are viewing this video outside of a desktop app, please switch to landscape mode or click the expand button on the right-hand side of the video screen.